Mutations in the kinase domain of BCR::ABL1 are the most extensively studied mechanism of TKI resistance in CML, but they fail to explain approximately 20% to 40% of resistant cases [2]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.